{"nct_id":"NCT03631732","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","status_verified_date":"2021-08","start_date":"2018-08-28","start_date_type":"ACTUAL","primary_completion_date":"2019-08-12","primary_completion_date_type":"ACTUAL","completion_date":"2020-08-19","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GILD"]}